Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$456 Mln
P/E Ratio
--
P/B Ratio
3.68
Industry P/E
--
Debt to Equity
0.01
ROE
-0.6 %
ROCE
-59.42 %
Div. Yield
0 %
Book Value
1.74
EPS
-1.34
CFO
$-100.65 Mln
EBITDA
$-595.71 Mln
Net Profit
$-244.03 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Altimmune (ALT)
| -21.78 | -11.46 | -32.86 | -42.80 | -7.17 | 13.53 | -36.10 |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Altimmune (ALT)
| -35.68 | -31.61 | 79.59 | -18.79 | 496.83 | -8.25 | -96.49 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.71 | 10,257.64 | 20.82 | 23.13 | |
| 33.86 | 13,384.89 | -- | -28.77 | |
| 109.77 | 11,042.16 | 33.66 | 14.16 | |
| 74.93 | 9,430.55 | 41.53 | 19.71 |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the... treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878 Read more
President, CEO & Director
Dr. Vipin K. Garg Ph.D.
President, CEO & Director
Dr. Vipin K. Garg Ph.D.
Headquarters
Gaithersburg, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Altimmune Inc (ALT) stood at $ 139 Mln as on 31-Dec-24
The share price of Altimmune Inc (ALT) is $5.64 (NASDAQ) as of 18-Mar-2025 15:34 EDT. Altimmune Inc (ALT) has given a return of -7.17% in the last 3 years.
Altimmune Inc (ALT) has a market capitalisation of $ 456 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Altimmune Inc (ALT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Altimmune Inc (ALT) and enter the required number of quantities and click on buy to purchase the shares of Altimmune Inc (ALT).
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Address: 910 Clopper Road, Gaithersburg, MD, United States, 20878
The CEO & director of Dr. Vipin K. Garg Ph.D.. is Altimmune Inc (ALT), and CFO & Sr. VP is Dr. Vipin K. Garg Ph.D..
There is no promoter pledging in Altimmune Inc (ALT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Altimmune Inc. (ALT) | Ratios |
|---|---|
|
Return on equity(%)
|
-59.86
|
|
Operating margin(%)
|
-475250
|
|
Net Margin(%)
|
-475295
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Altimmune Inc (ALT) was $0 Mln.
$-0.33
(
